A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Sickle Cell Disease, Thalassemia
About this trial
This is an interventional treatment trial for Sickle Cell Disease focused on measuring SCD, sickle cell disease, sickle cell, anemia, sickle cell anemia, hemolytic, hemoglobin, vaso-occlusive crisis, VOC, vaso-occlusive events, sickle cell crisis, pain crisis, pain episode, congenital anemia, hemolytic anemia, hematologic disease, hemoglobinopathy, hemoglobinopathies, genetic disease, inborn disease, sickle cell trait, pyruvate kinase, PKR, thalassemia, beta-thalassemia, alpha-thalassemia, transfusions, hemoglobin H, transfusion, transfusion-dependent, non-transfusion dependent, hemoglobin E
Eligibility Criteria
Inclusion Criteria:
- Provision of consent
- Female patients of childbearing potential must use acceptable methods of contraception, male patients are willing to use barrier methods of contraception
Cohort A (Sickle Cell Disease Transfusion Cohort)
- Confirmed diagnosis of sickle cell disease
- Chronically red blood cell transfused (sample or exchange [manual or via electrophoresis]) for primary stroke prevention or due to previous stroke. Chronic red blood cell transfusion is defined as: ≥ 6 red blood cell units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period
- At least 24 months of chronic monthly red blood cell transfusions for secondary stroke prevention/treatment of primary stroke (initial completed overt clinical stroke with documented infarction on brain computed tomography [CT] or magnetic resonance imaging [MRI])
- Prior to screening OR at least 12 months of chronic RBC transfusions for primary stroke prevention (abnormal TCD) prior to screening
- Documented adequate monthly transfusions with average HbS ≤ 45% (the upper limit of the established academic community standard) for the previous 12 weeks of red blood cell transfusions before the first dose of study treatment
Cohort B (Thalassemia Transfusion Cohort)
- Documented diagnosis of β-thalassemia, Hemoglobin E/ β-thalassemia or Hemoglobin H (α-thalassemia), or other thalassemia variant
- Chronically transfused, defined as: ≥ 6 red blood cell units in the previous 24 weeks before the first dose of study treatment and no transfusion-free period for > 35 days during that period
Cohort C (Thalassemia Non-transfused Cohort)
- Documented diagnosis of β-thalassemia, Hemoglobin E/ β-thalassemia or Hemoglobin H (α-thalassemia), or other thalassemia variant
- Hemoglobin ≤ 10 g/dL
Exclusion Criteria:
- Female who is breast feeding or pregnant
Hepatic dysfunction characterized by:
- Alanine aminotransferase (ALT) > 4.0 × upper limit of normal (ULN)
- Direct bilirubin > 3.0 × ULN
- History of cirrhosis
- Known human immunodeficiency virus (HIV) positivity
- Active hepatitis B or hepatitis C infection
- Severe renal dysfunction or on chronic dialysis
History of malignancy within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.
- Patients with malignancy considered surgically cured are eligible (eg, non- melanoma skin cancer, cancer of the cervix in-situ, ductal carcinoma in situ [Stage 1], Grade 1 endometrial cancer)
History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
- Unstable angina pectoris or myocardial infarction or elective coronary intervention
- Congestive heart failure requiring hospitalization
- Uncontrolled clinically significant arrhythmias
- Symptomatic pulmonary hypertension
Sites / Locations
- The Oncology Institute of Hope & InnovationRecruiting
- Children's Hospital Los AngelesRecruiting
- University of California, Los AngelesRecruiting
- University of California - San FranciscoRecruiting
- Children's Hospital of Orange CountyRecruiting
- UCI HealthRecruiting
- Children's NationalRecruiting
- Weill Medical College of Cornell UniversityRecruiting
- Duke Adult Comprehensive Sickle Cell CenterRecruiting
- East Carolina UniversityRecruiting
- Cincinnati Children's Hospital Medical CenterRecruiting
- Children's Hospital of PhiladelphiaRecruiting
- CHU Sainte-JustineRecruiting
- The Hospital for Sick ChildrenRecruiting
- Nini HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Etavopivat 400 mg daily - SCD with transfusions
Etavopivat 400 mg daily - Thalassemia with transfusions
Etavopivat 400 mg daily - Thalassemia
Patients with sickle cell disease on chronic red blood cell transfusions
Patients with thalassemia on chronic red blood cell transfusions
Patients with thalassemia not on chronic red blood cell transfusions